Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.

Autor: Coyle PK; Department of Neurology, Stony Brook Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA., Freedman MS; University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Cohen BA; Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA., Cree BAC; Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA., Markowitz CE; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jazyk: angličtina
Zdroj: Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2024 Apr; Vol. 11 (4), pp. 842-855. Date of Electronic Publication: 2024 Feb 16.
DOI: 10.1002/acn3.52017
Abstrakt: Four sphingosine 1-phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are approved by the US Food and Drug Administration for the treatment of multiple sclerosis. This review summarizes efficacy and safety data on these S1P receptor modulators, with an emphasis on similarities and differences. Efficacy data from the pivotal clinical trials are generally similar for the four agents. However, because no head-to-head clinical studies were conducted, direct efficacy comparisons cannot be made. Based on the adverse event profile of S1P receptor modulators, continued and regular monitoring of patients during treatment will be instructive. Notably, the authors recommend paying attention to the cardiac monitoring guidelines for these drugs, and when indicated screening for macular edema and cutaneous malignancies before starting treatment. To obtain the best outcome, clinicians should choose the drug based on disease type, history, and concomitant medications for each patient. Real-world data should help to determine whether there are meaningful differences in efficacy or side effects between these agents.
(© 2024 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje